USPTO Grants Patent for ACE Inhibitor and Blood Pressure-Lowering Agent
Summary
The USPTO has granted a patent (US12582146B2) to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent containing a specific compound. The patent also covers beverages and food products incorporating this compound.
What changed
The United States Patent and Trademark Office (USPTO) has granted patent US12582146B2 to MARUZEN PHARMACEUTICALS CO., LTD. for an angiotensin-converting enzyme (ACE) inhibitor and blood pressure-lowering agent. The patent claims a specific compound represented by formula (I) as the active ingredient, along with beverages and food products containing this compound. The patent was filed on September 2, 2020, and granted on March 24, 2026, with 12 claims.
This patent grant is primarily informational for the pharmaceutical and food manufacturing sectors. It does not impose new regulatory obligations or compliance deadlines on regulated entities. Compliance officers should note this as a development in intellectual property within the therapeutic area of cardiovascular agents, particularly for companies operating in the drug and functional food/beverage markets.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Angiotensin-converting enzyme inhibitor, blood pressure-lowering agent, and beverages and food products
Grant US12582146B2 Kind: B2 Mar 24, 2026
Assignee
MARUZEN PHARMACEUTICALS CO., LTD.
Inventors
Yosuke Nishitani
Abstract
This angiotensin-converting enzyme inhibitor and this blood pressure-lowering agent contain a compound represented by formula (I) as an active ingredient. These beverages and food products for inhibiting an angiotensin-converting enzyme and these beverages and food products for lowering blood pressure are characterized by containing a compound represented by formula (I). As a result, provided are an angiotensin-converting enzyme inhibitor and blood pressure-lowering agent that have an excellent angiotensin-converting enzyme-inhibiting effect and blood pressure-lowering effect. Furthermore, provided are beverages and food products suitable for inhibition of an angiotensin-converting enzyme and lowering of blood pressure.
CPC Classifications
A23L 33/10 A61P 9/12 A61K 31/192
Filing Date
2020-09-02
Application No.
17764666
Claims
12
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.